Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC

Podcast

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

In the video series, Bazhenova and Albrecht discussed the following:

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
Related Content